| University of Miami Patent applications |
| Patent application number | Title | Published |
|---|
| 20120135011 | Method for in vivo expansion of T regulatory cells - Compositions specific for TNF-receptor superfamily member 25 (TNFRSF25, DR3) modulate the immune response by regulating T regulatory cells. | 05-31-2012 |
| 20120129199 | COMPOSITIONS, KITS AND METHODS FOR IN VITRO ANTIGEN PRESENTATION, ASSESSING VACCINE EFFICACY, AND ASSESSING IMMUNOTOXICITY OF BIOLOGICS AND DRUGS - Nanoparticle-based compositions, assays, kits, methods and platforms for delivering an antigen (peptides, proteins) or a nucleic acid encoding an antigen to professional APCs (PAPCs) result in the generation of autologous APCs that present a natural peptide repertoire of the antigen for use in assessing the efficacy of a vaccine (e.g., a cytotoxic T lymphocyte (CTL) response to a particular antigen) or other therapy or intervention (cell-based therapy, adjuvant therapy, etc.). The compositions, kits, assays and methods also can be used for delivering a drug or biologic or portion thereof to APCs for assessing the immunogenicity of drugs and biologics. The composition, kits, assays and methods involve the combined use of MHC targeting, universal DR binding peptides (e.g., PADRE, HA) with charged (e.g., positively-charged) highly branched polymeric dendrimers (e.g., PAMAM and other dendrimers) as vehicles for the targeted delivery of nucleic acids, peptides, biologics, drugs, or polypeptides to APCs, giving rise to a new nanoparticle-based method for assessing the immune response (CTL response) to a vaccination or other therapy or intervention, or for assessing the immunogenicity of a biologic or drug. Targeted delivery of nucleic acids, peptides, biologics, drugs, or polypeptides to APCs for effective expression and processing generates more physiologically relevant target antigens for evaluation of cell-mediated immune responses to vaccination, for example, and provides a low-cost approach for rapid generation of reagents and development of assay systems for more accurate profiling of immunological responses to infection, immunization, and other therapies or interventions. Immunoevaluation kits using targeted nanoparticle-based antigen delivery are described herein. | 05-24-2012 |
| 20120115165 | BIOMARKERS FOR DETECTION AND DIAGNOSIS OF HEAD AND NECK SQUAMOUS CELL CARCINOMA - Novel, sensitive and specific markers and methods for diagnostics and monitoring of head and neck squamous cell carcinoma (HNSCC) are provided. Kits and methods for the use of hyaluronic acid, hyaluronidase and CD44 to diagnose HNSCC are described. | 05-10-2012 |
| 20120114729 | SILICONE-PEROXIDE COMPOSITIONS FOR LONG-TERM, CONTROLLED OXYGEN RELEASE - A composite for delivering extended-release of oxygen is disclosed. The composite can include a biocompatible polymeric support having a plurality of solid peroxide particles suspended therein. The polymer support can exhibit an oxygen tension value of at least 40 mmHg for a period of 14 days. The weight ratio of biocompatible polymeric support to solid peroxide particles can range from 1:1 to 99:1. Also disclosed is a method of using the composite to deliver oxygen to cells in both in vivo and in vitro environments. | 05-10-2012 |
| 20120101375 | INTRAOPERATIVE MONITORING OF TEMPERATURE-INDUCED TISSUE CHANGES WITH A HIGH-RESOLUTION DIGITAL X-RAY SYSTEM DURING THERMOTHERAPY - A method of thermally inducing and monitoring changes to localized regions of tissue illuminating a volume of tissue with a first beam of X-rays, detecting portions of the first beam that passed through the volume, generating a first image signal from the portions of the first beam detected, applying heat to at least a localized region of tissue within the volume after the illuminating and detecting, illuminating the volume with a second beam of X-rays, detecting portions of the second beam that passed through the volume during the illuminating with the second beam, generating a second image signal from the portions of the second beam detected, and generating a difference image signal based upon a comparison of the first and second image signals. The difference image signal provides information of changes in X-ray attenuation by localized regions of tissue within the volume due to the application of heat. | 04-26-2012 |
| 20120093761 | VACCINE COMPOSITIONS AND METHODS OF USE THEREOF - Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g. tumor cells). Antigens may be, for example, DNA that results in expression of the gene of interest and induction of a robust and specific immune response to the expressed protein in a subject (e.g., mammal). Antigens may also be immunogenic peptides or polypeptides that are processed and presented. In one embodiment, a nanoparticle -based method to deliver antigens in vivo as described herein includes injection of a vaccine composed of a DNA encoding at least one antigen, or at least one antigenic peptide or polypeptide conjugated to a charged dendrimer (e.g., PADRE-derivatized dendrimer) that is also conjugated to a T helper epitope (e.g., PADRE). Negatively-charged plasmids bind naturally to a positively-charged PADRE-dendrimer, while peptide or polypeptide antigens can be chemically linked to the PADRE-dendrimer if they are not negatively-charged. Alternatively, negatively-charged dendrimers may be used. The compositions, kits, vaccines and methods described herein have both prophylactic and treatment applications, i.e., can be used as a prophylactic to prevent onset of a disease or condition in a subject, as well as to treat a subject having a disease or condition. A vaccine as described herein can be used to mount an immune response against any infectious pathogen or cancer. | 04-19-2012 |
| 20120071911 | SPHERICAL HELIX EMBOLIC COILS FOR THE TREATMENT OF CEREBRAL ANEURYSMS - A method and device for occluding an aneurysm. The device may include a wire having a shape memory. The wire may define a coil. The wire may further define a first substantially spherical helix and a second substantially spherical helix nested within the first substantially spherical helix. A catheter may be included, being releaseably engageable to the wire, the wire being at least partially disposed within the catheter. | 03-22-2012 |
| 20120070511 | MITOCHONDRIAL INHIBITORS AND USES THEREOF - Compositions which modulate mitochondrial functions treat diseases associated with cells that are hyperactively using their endoplasmic reticulum. Screening assays identify agents which modulate mitochondrial functions. | 03-22-2012 |
| 20120055810 | SOLID-STATE ELECTROCHEMICAL SENSOR - A method and system for corrosion detection. The system may comprise an electrochemical sensor having a working electrode, a reference electrode, a counter electrode, and a polymer electrolyte film containing redox pairs. The electrochemical sensor may further be engaged with a guide element. A console may be included, the console being coupled to the guide element and in electrical communication with the electrochemical sensor. | 03-08-2012 |
| 20120037751 | SUPERSONIC FLYING WING - A bidirectional flying wing maximizes efficiency and reduces sonic boom during supersonic flight. The flying wing has bilateral symmetry across two perpendicular planes and a substantially isentropic compression bottom surface that minimizes the shock wave projected downward during flight. The flying wing may be rotated to provide a high aspect ratio and a low sweep angle during subsonic flight. The flying wing may be rotated to provide a low aspect ratio and a high sweep angle during supersonic flight. | 02-16-2012 |
| 20120029472 | TNFR25 AGONISTS TO ENHANCE IMMUNE RESPONSES TO VACCINES - TNFR25 compositions enhance the immune response against antigens. Administration of TNFR25 agonists was found to enhance tumor rejection, responses against viral diseases and other infectious organisms. | 02-02-2012 |
| 20120027670 | SELF SUSTAINED ELECTROCHEMICAL PROMOTION CATALYSTS - A method and system for the reduction of pollutant NOx gases from automobile exhaust, as well as a method of reforming hydrocarbons, using a self-sustaining catalyst comprising an ion conductive support, a dispersed cathodic phase, a dispersed anodic phase, and a dispersed sacrificial phase, and a method of forming the self-sustaining catalyst. | 02-02-2012 |
| 20120006183 | AUTOMATIC ANALYSIS AND MANIPULATION OF DIGITAL MUSICAL CONTENT FOR SYNCHRONIZATION WITH MOTION - Systems and methods are provided for extracting rhythmic chroma information from a signal. A method may perform a process for rhythmic event perception, periodicity estimation, and chroma representation. Such a process may be implemented by a digital signal processor. The method may further include time-stretching a music signal so that a rhythm of the music signal matches a rhythm of motion detected by a motion sensor. | 01-12-2012 |
| 20110287961 | EXPRESSION ANALYSIS OF CORONARY ARTERY ATHEROSCLEROSIS - This invention relates, e.g., to a method for screening a subject for the presence of coronary atherosclerosis, said method comprising measuring the expression level of at least 5 of the genes of Table 2 in a biological sample obtained from said subject, wherein an elevated level of expression of said 5 genes compared to a control level measured in a population of normal subjects is indicative of an increased probability of the subject having significant subclinical coronary atherosclerosis. Methods for deciding on a treatment modality, based on a diagnostic procedure of the invention, are also described, as are kits for carrying out a method of the invention. | 11-24-2011 |
| 20110287057 | Cancer Treatment - A cell-based vaccine prolongs the survival of cancer patients. The vaccine includes a dose of irradiated cultured lung adenocarcinoma cells (AD100) transfected with HLA A1 and gp96-Ig (human gp96 wherein the endoplasmic reticulum retention signal, KDEL, is replaced with the Fc-portion of human IgG1 and was injected intradermally into patients suffering from advanced, relapsed, or metastatic NSCLC. Administration of the vaccine increased the mean survival time of the patients compared to that of similar patients treated with placebo. Moreover, the immune response of patients to the vaccine (antigen-induced interferon gamma production by T cells) correlated with the survival times. | 11-24-2011 |
| 20110275931 | System and Method for Early Detection of Diabetic Retinopathy Using Optical Coherence Tomography - A system for the imaging, processing and evaluation of tissues provides prognostic and diagnostic details regarding diseased tissue. A set of quantitative measures were developed and integrated in an image-base analysis software tool designed for OCT images. The system and methods in this invention is significant because it allows assessing the optical properties and structure morphology differences between normal healthy subjects and diabetic patients with retinopathy up to ETDRS level 35 and without retinopathy. | 11-10-2011 |
| 20110273667 | ENHANCED OPTICAL COHERENCE TOMOGRAPHY FOR ANATOMICAL MAPPING - A system, method and apparatus for anatomical mapping utilizing optical coherence tomography. In the present invention, 3-dimensional fundus intensity imagery can be acquired from a scanning of light back-reflected from an eye. The scanning can include spectral domain scanning, as an example. A fundus intensity image can be acquired in real-time. The 3-dimensional data set can be reduced to generate an anatomical mapping, such as an edema mapping and a thickness mapping. Optionally, a partial fundus intensity image can be produced from the scanning of the eye to generate an en face view of the retinal structure of the eye without first requiring a full segmentation of the 3-D data set. Advantageously, the system, method and apparatus of the present invention can provide quantitative three-dimensional information about the spatial location and extent of macular edema and other pathologies. This three-dimensional information can be used to determine the need for treatment, monitor the effectiveness of treatment and identify the return of fluid that may signal the need for re-treatment. | 11-10-2011 |
| 20110262485 | STING (STIMULATOR OF INTERFERON GENES), A REGULATOR OF INNATE IMMUNE RESPONSES - Novel molecules termed STING which include nucleic acids, polynucleotides, oligonucleotides, peptides, mutants, variants and active fragments thereof, modulate innate and adaptive immunity in a subject. STING compositions are useful for the treatment of an immune-related disorder, including treating and preventing infection by modulating immunity | 10-27-2011 |
| 20110251236 | GALACTOKINASE INHIBITORS - Therapeutic agents for treatment of Galactosemia and disorders thereof, and other enzyme related disorders thereof are identified. The compounds inhibit galactokinase (GALK) and other kinase activity and are identified by a high throughput screening assay. | 10-13-2011 |
| 20110243951 | IMMUNOMODULATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS AND IMMUNOTOXINS - It is an object of the invention to provide novel compositions and methods utilizing immunomodulating agents that can either stimulate or indirectly augment the immune system or in other cases have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, among other things, to treat disease caused by asthma and chronic inflammation such as for example inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein are capable of inhibiting CD8 T cell-mediated cellular immune responses and can for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines. TNFR25 specific immunotoxins disclosed herein are also capable of increasing the effectiveness of a chemotherapeutic regimen by depleting a cancer patient of naturally occurring immunosuppressive cells. | 10-06-2011 |
| 20110236397 | LIMITED PROTEOLYSIS OF CD2AP AND PROGRESSION OF RENAL DISEASE - Compositions which specifically block cathepsin L function in podocytes, compositions which protect cytoskeletal adaptor protein (CD2AP) for degradation, compositions which modulate expression or function of cytoskeletal adaptor protein (CD2AP), protect against renal diseases or disorders. Methods of treatment in vivo involve use of one or more compositions. | 09-29-2011 |
| 20110236356 | METHODS OF ISOLATING AND USING STEM CELLS - Methods of isolating and using stem cells from neural crest, e.g. periodontal ligament, isolated stem cell and therapeutic cell cultures, and therapeutic applications for a variety of conditions. The cells and cell cultures are especially useful for autologous administration. | 09-29-2011 |
| 20110234976 | RETINAL IMAGING SYSTEM FOR THE MOUSE OR RAT OR OTHER SMALL ANIMALS - A small animal imaging system comprising a base element and a camera coupled to the base element, the camera being sized to image the eye of a small animal. A light-emitting diode is also included coupled to the base element. An OCT imaging apparatus is also included coupled to the base element. An X-Y scanner is also included coupled to the base element in communication with the OCT imaging apparatus. | 09-29-2011 |
| 20110228223 | SPECTRAL CONTRAST FOR GLAUCOMA IMAGING - A system for analyzing and detecting early stage damage to the retina related to glaucoma. The reflectance of different wavelengths of light by the retinal nerve fiber layer are compared. Changes in relative reflectance values indicate damage to the retinal nerve fibers and indicate early glaucomatous optical neuropathy. | 09-22-2011 |
| 20110223196 | HIV/SIV VACCINES FOR THE GENERATION OF MUCOSAL AND SYSTEMIC IMMUNITY - Compositions of genetically engineered, secreted gp96 (gp69-Ig) induced strong mucosal and systemic immune responses and CD8 expansion that was independent of CD4 help. Immunization of patients with gp96-Ig immunization is especially attractive for induction of mucosal and systemic immunity to SIV/HIV and other diseases. | 09-15-2011 |
| 20110210211 | DISCRETE CO-FLOW JET (dCFJ) AIRFOIL - The present invention provides an aircraft having one or more fixed wings in a flying wing configuration, where the aircraft further includes a high performance co-flow jet (CFJ) circulating about at least a portion of an aircraft surface to produce both lift and thrust. | 09-01-2011 |
| 20110208305 | COMPOSITE BONE GRAFTS, PARTICULATE BONE-CALCIUM SULFATE CONSTRUCTS, AND METHODS OF TREATING JOINT INJURIES - A solid implantable bone construct ( | 08-25-2011 |
| 20110207628 | OPEN-READING-FRAME (ORF) PHAGE DISPLAY - A dual display phage system for the identification of protein interaction networks and therapeutic targets. | 08-25-2011 |
| 20110201008 | ASSAYS, METHODS AND KITS FOR MEASURING RESPONSE TO THERAPY AND PREDICTING CLINICAL OUTCOME IN PATIENTS WITH B-CELL LYMPHOMA - Assays, methods and kits for predicting survival outcome in a subject having diffuse large B-cell lymphoma (DLBCL) and for measuring a subject's response to DLBCL therapy involve specific miRNAs that are prognostic biomarkers for prediction of outcome of DLBCL patients. Expression of miRNAs miR-18a, miR-181a and miR-222 is associated with response to therapy and outcome of patients with DLBCL. Measurement of these miRs can be used to identify patients' outcomes in the clinic and allow tailoring of patient-specific therapy. | 08-18-2011 |
| 20110184298 | PORTABLE CARDIO WAVEFORM ACQUISITON AND HEART RATE VARIABILITY (HRV) ANALYSIS - A system and method for measuring heart rate variability (HRV). The system includes at least one biosensor operable to measure at least one signal from the heart. A bioamplifier is also included, the bioamplifier is in communication with the at least one biosensor. The bioamplifier amplifies the at least one signal into at least one amplified analog signal. A portable device is included, the portable device is in communication with the bioamplifier and operable to digitize the at least one amplified signal into one or more digital signals and measure inter-beat intervals from the one or more digital signals and calculate HRV from the measured inter-beat intervals. A database is also included in communication with the portable device, wherein the measured HRV is indexed in the database by one or more criteria. | 07-28-2011 |
| 20110183926 | TREATMENT USING CONTINUOUS LOW DOSE APPLICATION OF SUGAR ANALOGS - Methods and uses of low dosage nonmetabolizable D-glucose analogs and mannose analogs such as 2-deoxy-D-glucose, 5-thio-D-glucose, 2-fluoro-2-deoxy-D-glucose, 2-chloro-2-deoxy-D-glucose, 2-bromo-2-deoxy-D-glueose, 2-deoxy-2-fluoro-mannose, 2-deoxy-2-chloro-mannose, 3-deoxy mannose, 4-deoxy mannose, and 2,3 didioxy mannose, for the treatment of tumors. | 07-28-2011 |
| 20110183922 | PEPTIDES THAT ENHANCE ACETYLCHOLINESTERASE EXPRESSION - The present invention provides novel chimeric peptides and novel methods for treating animals including humans by administering the novel chimeric peptides. In particular, the invention is useful for enhancing endogenous acetylcholinesterase expression in individuals exposed to organophosphate compounds, such as nerve gases and pesticides. | 07-28-2011 |
| 20110182866 | ISOLATION OF STEM CELL PRECURSORS AND EXPANSION IN NON-ADHERENT CONDITIONS - Stem cells and compositions thereof are isolated, cultured and expanded. Culture conditions and methods of culturing the isolated stem cells provide non-adherent stem cells which are prophylactically and therapeutically more effective in patients, diagnostics, screening assays and other stem cell uses. | 07-28-2011 |
| 20110147411 | PINCH MANIFOLD - The present invention includes substance delivery control system having a first conduit defining a lumen for the passage of a substance therethrough; a first delivery control element defining a first conduit state selection element; a second delivery control element defining a second conduit state selection element, where the alignment of the first and second conduit state selection elements places the conduit in a first state, and where misalignment of the first and second conduit state selection elements places the conduit in a second state. | 06-23-2011 |
| 20110123441 | NOVEL GREB1A MONOCLONAL ANTIBODY - The generation and validation of a novel monoclonal GREB1 antibody (GREB1ab). Methods for the prognosis, diagnosis, assessment of disease progression, severity and outcome utilize GREB1 molecules as biomarkers. The GREB1 antibody is also a useful tool for investigations focused on the expression, distribution and function of GREB1 in normal and cancer tissues. | 05-26-2011 |
| 20110108602 | ANASTOMOSIS SYSTEM AND METHOD - A system for performing anastomosis includes a plurality of staples, an annular staple support having structure for holding the staples, and a staple closing device for closing the staples to secure the canal ends together. A method for performing anastomosis and staples for performing anastomosis are also disclosed. | 05-12-2011 |
| 20110065675 | AZO DYE RELATED SMALL MOLECULE MODULATORS OF PROTEIN-PROTEIN INTERACTIONS - Azo dyes and suramin-related small molecules are effective in inhibiting the CD40/CD154 protein-protein interaction, an important co-stimulatory interaction involved in the activation of immune responses mediated by T- and B-cells. The compounds were found to be active as indicated by their IC | 03-17-2011 |
| 20110039788 | COMPOSITIONS, METHODS AND KITS FOR DETECTING AND TREATING CANCER - Compositions, kits and methods for inhibiting cancer cell (e.g., breast cancer cell) growth and treating a subject with cancer (e.g., breast cancer) include a therapeutically effective amount of an LBH inhibitor for inhibiting cancer cell growth and a pharmaceutically acceptable carrier, and/or a therapeutically effective amount of Wnt7a protein or nucleic acids encoding Wnt7a protein for inhibiting cancer cell growth and a pharmaceutically acceptable carrier. Methods of treating a subject having cancer (e.g., estrogen receptor negative basal-type breast cancer) include administering to the subject a composition including a pharmaceutical carrier and at least one of: an LBH inhibitor, a WNT7a protein, and a nucleic acid encoding WNT7a protein in an amount effective for inhibiting growth of cancer cells in the subject. Methods of detecting the presence of cancer (e.g., estrogen receptor negative basal-type breast cancer) in a subject include obtaining a biological sample from the subject; contacting the sample with at least one reagent that detects presence of LBH expression; measuring the level of LBH expression in the biological sample; and correlating overexpression of LBH with the presence of cancer (e.g., estrogen receptor negative basal-type breast cancer) in the subject. Kits for detecting the presence of basal-type breast cancer in a subject include at least one reagent for detecting the presence of LBH expression in a biological sample from the subject and instructions for use. | 02-17-2011 |
| 20110038865 | ANTIBODY- ENDOSTATIN FUSION PROTEIN AND ITS VARIANTS - Chimeric molecules comprising endostatin and all or a portion of a tumor antigen specific binding molecule for use in treating tumors. The chimeric molecule, includes endostatin, endostatin mutants and variants and an antibody or aptamer specific for a desired tumor antigen. Methods of treating cancer comprise administering the chimeric fusion molecules. | 02-17-2011 |
| 20110034931 | METHOD FOR PREPARING RECIPIENT SITE AND IMPLANTING ALLOGENIC BONE GRAFT - A method of fixating allogeneic bone to an area of deficient bone in the jaws comprising: exposing the area of deficient bone by incising and retracting soft tissue; selecting a drill bit having a diameter corresponding to the area of deficient bone to receive donor bone; contacting the selected drill bit with the exposed deficient bone to form a generally cylindrical seat for receiving the donor bone; selecting a section of donor bone having a generally cylindrical shape and circular cross-section corresponding to said formed seat; fixating the donor bone to the formed seat with at least one screw; and closing the soft tissue to cover the previously exposed deficient bone. | 02-10-2011 |
| 20110027313 | VIRAL RECOMBINEERING AND USES THEREOF - The invention uses recombinant technology to create infectious molecular clones that capture the sequence diversity of viral genes found in natural populations of mixed genotype viruses, such as arises during HIV infections and many other viral diseases. The invention captures the sequence diversity of different genes in these “quasi-species” populations by recombining them into in a constant genetic “backbone” for each viral species by backcrossing PCR products derived from quasispecies gene variants into this backbone in an | 02-03-2011 |
| 20110021584 | Methods and Assays for Detecting and Treating Hypoglycemia - Methods for regulating glucagon release and of treating hypoglycemia, and for screening drug candidates for treating hypoglycemia. The methods are useful for treating diabetes mellitus and screening drug candidates for potential efficacy. | 01-27-2011 |
| 20110020856 | PERIFUSION DEVICE - A perifusion device includes at least one sample container for cells, the sample container having an inlet and an outlet. The container receives test liquid through the inlet and discharges the liquid through the outlet. A manifold having a plurality of liquid inlets, control valves, and liquid outlets can be provided so that the flow of liquids from source containers to the sample containers can be varied and controlled. A receptacle housing has a plurality of receptacles for receiving fluid from the outlet of the sample container. A drive is connected to the receptacle housing for moving the receptacle housing such that liquid samples are collected sequentially from the outlet of the sample containers. A programmable controller can be provided to control movement of the receptacle housing at predetermined times, and to record data identifying liquid samples in the receptacles. The test liquid includes at least one stimuli for the cells, which can be the presence, absence, or concentration of a compound in the liquid, or a physical property of the liquid such as temperature. The liquid collected in the receptacles is analyzed to determine the response of the cells to the stimuli. | 01-27-2011 |
| 20100316622 | DIAGNOSIS AND TREATMENT OF CARDIAC DISORDERS - Nitric oxide synthase deficiency causes diminished ryanodine receptor S-nitrosylation leading to increased diastolic calcium (Ca | 12-16-2010 |
| 20100310532 | GENE TARGETS IN ANTI-AGING THERAPY AND TISSUE REPAIR - Novel gene and protein targets are described for treatment of cardiac disorders, anti-aging therapies and tissue repair. Identified biomarkers are prognostic of long term survival of patients suffering from heart diseases and related disorders. | 12-09-2010 |
| 20100298438 | GENE EXPRESSION PROFILING OF PARKINSON'S DISEASE - The present invention identifies the changes in gene expression associated with Parkinson's Disease by examining multiregional gene expression from normal brain and brain of Parkinson's Disease. The present also identifies the changes in gene expression associated with Parkinson's Disease by examining the expression of genes from normal blood and from the blood of patients with Parkinson's Disease. In another aspect, the present invention identifies expression profiles which serve as useful diagnostic markers as well as markers that can be used to monitor disease states, disease progression, drug toxicity, drug efficacy and drug metabolism. | 11-25-2010 |
| 20100285132 | IMMUNOTHERAPY COMPOSITIONS, METHOD OF MAKING AND METHOD OF USE THEREOF - The present invention directs to compositions and methods for modulating immune system. One aspect of the present invention relates to a composition comprising FADD-dependent signaling pathway modulators. Another aspect of the 5 present invention relates to biodegradable microparticles, such as a chitosan microparticic, or PLGA/PEI microparticle, designed to deliver nucleic acids and/or proteins, such as FADD-dependent signaling pathway modulators, to boost different pathways of an immune response. Another aspect of the present invention relates to the method of making biodegradable microparticles. The further aspect of the present invention relates to the use of the chitosan and other polycationic microparticles to deliver FADD-dependent signaling pathway modulators to modulate immune system for the prevention and/or treatment infectious diseases and cancers. | 11-11-2010 |
| 20100260727 | METHOD TO AMPLIFY CARDIAC STEM CELLS IN VITRO AND IN VIVO - Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes. | 10-14-2010 |
| 20100247302 | WIND ENERGY SYSTEM - A method and system for harvesting wind energy. The system may include a wind turbine disposed subjacent to a roof assembly of building. A plurality of conduits are adjacent to and extending below the wind turbine, wherein each of the plurality of conduits defines a first portion and a second portion, wherein the first portion defines a larger cross-sectional area than the second portion. | 09-30-2010 |
| 20100240732 | APTAMER-TARGETED SIRNA TO PREVENT ATTENUATION OR SUPPRESSION OF A T CELL FUNCTION - Compositions for countering immune attenuating/suppressive pathways comprise targeting agents or aptamer targeted RNAi-mediated gene silencing (siRNA/shRNA). These compositions have broad applicability in the treatment of many diseases. | 09-23-2010 |
| 20100208201 | ENHANCED OPTICAL COHERENCE TOMOGRAPHY FOR ANATOMICAL MAPPING - A system, method and apparatus for anatomical mapping utilizing optical coherence tomography. In the present invention, 3-dimensional fundus intensity imagery can be acquired from a scanning of light back-reflected from an eye. The scanning can include spectral domain scanning, as an example. A fundus intensity image can be acquired in real-time. The 3-dimensional data set can be reduced to generate an anatomical mapping, such as an edema mapping and a thickness mapping. Optionally, a partial fundus intensity image can be produced from the scanning of the eye to generate an en face view of the retinal structure of the eye without first requiring a full segmentation of the 3-D data set. Advantageously, the system, method and apparatus of the present invention can provide quantitative three-dimensional information about the spatial location and extent of macular edema and other pathologies. This three-dimensional information can be used to determine the need for treatment, monitor the effectiveness of treatment and identify the return of fluid that may signal the need for re-treatment. | 08-19-2010 |
| 20100183584 | CONFORMATION AND ACTIVITY OF GBETA5 COMPLEXES - The invention provides novel recombinant Gβ | 07-22-2010 |
| 20100160230 | UBIQUITIN AND UBIQUITIN RELATED MOLECULES FOR TREATMENT AND PREVENTION OF HARMFUL ACTIVATION OF THE IMMUNE SYSTEM - Compositions and methods for suppressing the immune system of a mammal using ubiquitin and derivatives and analogs thereof. | 06-24-2010 |
| 20100127129 | High performance airfoil with co-flow jet flow control - An aerodynamic system providing an airfoil having a chord length, a leading edge, and a trailing edge. The airfoil further includes a first airfoil surface extending from the leading edge to the trailing edge, a second airfoil surface opposite the first airfoil surface, extending from the leading edge to the trailing edge, an injection opening in the first airfoil surface, and a recovery opening in the first airfoil surface located between the injection opening and the trailing edge. A pressurized fluid source is in fluid communication with the injection opening and a vacuum source is in fluid communication with the recovery opening. An exemplary use of the aerodynamic system of the present invention provides the ejection of a mass of fluid out of the injection opening along a surface of the airfoil and drawing a mass of fluid into the recovery opening. | 05-27-2010 |
| 20100113567 | Recombinant VSV For The Treatment of Tumor Cells - The present invention relates to compositions and methods for the treatment of tumor and/or malignant and/or cancerous cells. The present invention provides VSV vectors comprising nucleic acid encoding a cytokine, such as interleukin or interferon, or a suicide gene, such as thymidine kinase, or other biological protein, such as heat shock protein gp96, or endostatin or angiostatin, wherein said VSV vectors exhibit greater oncolytic activity against the tumor and/or malignant and/or cancerous cell than a wild-type VSV vector. The present invention also provides methods of making such vectors, host cells, expression systems, and compositions comprising such VSV vectors, and viral particles comprising such VSV vectors. The present invention also provides methods for producing oncolytic activity in a tumor and/or malignant and/or cancerous cell comprising contacting said cell with a VSV vector of the present invention. The present invention also provides methods for suppressing tumor growth comprising contacting said tumor with a VSV vector of the present invention. The present invention also provides methods for eliciting an immune response to a tumor cell in an individual. | 05-06-2010 |
| 20100112587 | TRANSCRIPTOMIC BIOMARKERS FOR INDIVIDUAL RISK ASSESSMENT IN NEW ONSET HEART FAILURE - A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure. | 05-06-2010 |
| 20100062048 | TOPICAL CO-ENZYME Q10 FORMULATIONS AND TREATMENT OF PAIN, FATIGUE AND WOUNDS - CoQ1O has a stimulatory effect on fibroblasts and keratinocytes, increases ATP production, decreases pain. The formulations are useful for promoting acute wound healing, fatigue and treatment of acute and chronic pain. | 03-11-2010 |
| 20100003679 | ASSESSMENT OF CELLULAR COMPOSITION AND FRACTIONAL VIABILITY AND USES THEREOF - A method of assessing cellular composition and fractional viability that can be predictive of post-transplant cell potency and transplantation outcome, comprises identifying cellular composition and assessing cellular viability. This has particular importance in the field of tissue and cell transplantation, cell therapy and regenerative medicine, providing a method for tissue and cell characterization, viability and potency testing, that could be useful for the definition of product release criteria for research and clinical applications. | 01-07-2010 |
| 20090325897 | DESIGNER THERAPY OF PANCREATIC TUMORS - Chemotherapeutic and Radiation sensitizing agents which target tumor cells, specifically, based on the elevation of enzyme pathways, provide highly selective drug therapy. These agents are combined with modulating doses of cytidine deaminase inhibitors to increase selectivity. Furthermore, high doses of these cytidine deaminase inhibitors have the potential of counteracting the aggressive and metastatic characteristics of pancreatic tumors. For tumors with high levels of cytidine deaminase, such as pancreatic tumors, this elevation provides a therapeutic approach with prodrugs that require deamination for their activation. For tumors with high levels of uridine/cytidine kinase, a different class of pyrimidine analogs can be activated selectively in tumors for a therapeutic advantage. | 12-31-2009 |
| 20090325201 | Biomarkers for Detection and Diagnosis of Head and Neck Squamous Cell Carcinoma - Novel, sensitive and specific markers and methods for diagnostics and monitoring of head and neck squamous cell carcinoma (HNSCC) are provided. Kits and methods for the use of hyaluronic acid, hyaluronidase and CD44 to diagnose HNSCC are described. | 12-31-2009 |
| 20090305251 | BRCA1/BRCA2 SCREENING PANEL - A method for analyzing a biological sample is performed by analyzing a biological sample for the presence of one or more mutations or polymorphisms in the BCRA1 and/or BCRA2 genes. | 12-10-2009 |
| 20090299100 | Fossil Fuel Desulfurization - A method for oxidizing an organic sulfide by combining an alkali borate, a solvent, hydrogen peroxide, and the organic sulfide, and allowing the alkali borate, the hydrogen peroxide, and the organic sulfide to interact to produce an oxidized organic sulfide. | 12-03-2009 |
| 20090274687 | ATTENUATION OF HYPOXIA INDUCED CARDIOVASCULAR DISORDERS - Blockade of stromal derived factor-1 (SDF-1), a stem cell mobilizer and/or its receptor, chemokine receptor 4 (CXCR4) attenuates and reverses hypoxia-induced cardiopulmonary remodeling in vivo. Compositions for treating hypoxia-induced cardiovascular disorders modulate the SDF-1/CXCR4 axis. | 11-05-2009 |
| 20090270690 | SYSTEM AND METHOD FOR USING INTERACTIVE VOICE-RECOGNITION TO AUTOMATE A PATIENT-CENTERED BEST PRACTICE APPROACH TO DISEASE EVALUATION AND MANAGEMENT - A method and system for monitoring, evaluating, and improving effectiveness and efficiency for treating chronic medical conditions of a large patient population. The inventive method and system utilizes computerized patient interview and data analysis modules for assessing a patient's condition and indicating a need for medical attention. Patient interviews are regularly conducted by telephone using computer generated questions and voice recognition methods to enter responses into a database. A series of medical questions are developed and presented to the patient. Their answers are recorded and analyzed with respect to the database. Based upon the answers and the analysis thereof, a medical action plan is developed, care instructions provided, and an appointment with a doctor scheduled. | 10-29-2009 |
| 20090221698 | MANNOSE DERIVATIVES FOR KILLING TUMOR CELLS - A method for treating cancer by killing selected tumor cells such as human breast, non-small cell lung cancer cells, pancreatic cancer cells, osteosarcoma cancer cells, and glioblastoma cells, includes administering to a patient in need of treatment, an effective amount of at least one mannose analog such as 2-DG or 2-FM or 2-CM. The killing is believed to be due to an interference with glycosylation. A theranostic method includes determining whether a patient. cancer tumor sample comprises cells sensitive to killing to at least one mannose analog due to an interference with glycosylation. | 09-03-2009 |
| 20090161870 | METHOD FOR KEYLESS PROTECTION OF DATA USING A LOCAL ARRAY OF DISKS - A method secures data in a network. The data includes a data message that has a first bit length. A random number is generated and transformed to create a first pseudo random number. The first pseudo random number is mixed with the data message to create an encrypted message. The encrypted message is transformed into a second pseudo random number. The second pseudo random number is mixed with the random number to produce a key. The encrypted message is placed side-by-side with the key to produce an output message. The output message is dispersed into a plurality of fragments. The plurality of fragments is stored in a plurality of data storage devices | 06-25-2009 |
| 20090142768 | PERFORIN-2 PROTEINS - Perforin-2 (P2) molecule is a pore forming protein. The 5′ untranslated region of the perforin-2 protein controls translational activity. Compositions include the perforin protein and the 5′ untranslated region. Methods of use include high-throughput screening assays for identification of therapeutic compounds in treatment of diseases. | 06-04-2009 |
| 20090136463 | Schwann Cell Bridge Implants and Phosphodiesterase Inhibitors to Stimulate CNS Nerve Regeneration - The use of a composition that elevates intracellular levels of cyclic nucleotide cyclases in combination with phosphodiesterase inhibitors and cell grafts to restore function after CNS injury. | 05-28-2009 |
| 20090104200 | MODULATING INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE CENTRAL NERVOUS SYSTEM - Compositions and methods for reducing inflammation in the central nervous system (CNS) of a mammal that has been subjected to a stroke, traumatic injury to the CNS such as traumatic brain injury (TBI), spinal cord injury (SCI), or having an autoimmune or CNS disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., ASC, NALP1) in a mammalian inflammasome (e.g., the NALP1 inflammasome) and have use as treatments for SCI, TBI, stroke, and autoimmune and CNS diseases in a mammal. In a rodent model of SCI, therapeutic neutralization of ASC using a polyclonal antibody that specifically binds to ASC inhibited the inflammasome, reduced caspase-1 activation, XIAP cleavage, and interleukin processing, resulting in significant tissue sparing and functional improvement. Additionally, in a rodent model of TBI, neutralization of ASC after TBI reduced caspase-1 activation and XIAP cleavage. Further, in a rodent thromboembolic stroke model, neutralization of NLRP1 resulted in reduced histopathological damage in mice and reduced cytokine activation, suggesting that the inflammasome complex forms in the brain after stroke and is a therapeutic target for reducing the detrimental consequences of post-stroke inflammation. | 04-23-2009 |
| 20090065631 | EMISSIONLESS SILENT AND ULTRA-EFFICIENT AIRPLANE USING CFJ AIRFOIL - The present invention provides an aircraft having one or more fixed wings in a flying wing configuration, where the aircraft further includes a high performance co-flow jet (CFJ) circulating about at least a portion of an aircraft surface to produce both lift and thrust rather than a conventional propulsion system (i.e., a propeller or jet engine). | 03-12-2009 |
| 20090062204 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING GASTROENTERIC DISEASES - A model system to study extracellular enteric bacterial pathogen (e.g., | 03-05-2009 |
| 20080299100 | Topical Co-Enzyme Q10 Formulations and Methods of Use - Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals. | 12-04-2008 |
| 20080286746 | PERFUSION APPARATUS AND METHOD - A perfusion apparatus for perfusing an organ includes a pump for pumping perfusion liquid though a perfusion liquid conduit, the conduit having an outlet. A pressure sensor senses the pressure of the perfusion liquid downstream of the pump and upstream of the outlet. A controller controls the output of the pump responsive to the pressure, so as to keep the pressure of the liquid reaching the organ substantially constant. | 11-20-2008 |
| 20080233119 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY LUNG DISEASE - The invention provides a method of modulating a T cell immune response by modulating DR3 function in the T cell, wherein the T cell response causes a symptom of inflammatory lung disease. The invention also provides a method of treating a reactive airway disease in an animal subject by administering to the subject an agent which modulates at least one functional activity of CD30. The invention additionally provides a method for treating an inflammatory lung disease by administering an agent that decreases the activity of DR3 or CD30, whereby IL-13 expression is decreased. | 09-25-2008 |
| 20080213625 | Optical Data Storage and Retrieval Based on Fluorescent and Photochromic Components - An optical storage medium | 09-04-2008 |
